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To antagonize tumor-derived TGFb contemporaneously to anticancer immunotherapy, we genetically engineered a
fusion protein coupling IL-2 and the ectodomain of TGFb receptor II (Fusion of Interleukin-2 and Soluble TGFb receptor –
a.k.a. FIST). FIST possesses intriguing gain-of-function properties and induces potent activation of IL2-receptor expressing
cells and inhibits tumor-derived angiogenesis. Thus FIST constitutes a first-in-class biological that couples anti-
angiogenesis to an immune antitumor response.
TGFb Role in Tumor Progression
The balance between proliferative and
inhibitory signals is essential to maintain
immune homeostasis. In late stage tumor
progression, immunostimulatory signals
provide by proinflammatory cytokines are
antagonized by tumor derived immuno-
suppressive cytokines, such as TGF . The
members of the Transforming Growth
Factor   (TGF ) family are cytokines
involved in essential cellular functions
such as proliferation, differentiation, apop-
tosis, tissue remodeling, angiogenesis,
immune response, cell adhesion, and also
play a key role in pathophysiology of
disease states such chronic inflammatory
conditions and cancer.
1 The members of
this family include the three isoforms of
TGF s,  1,  2,  3; bone morphogenetic
proteins (BMPs) and activins. Among
them, TGF 1 is the most frequently
overexpressed by carcinomas.
2 TGF , the
most potent immunosuppressive cytokine
described to date, exerts severe deleterious
effects on several components of the
immune system response against cancer
cells. TGF  abolishes the effector func-
tions of macrophages, B cells, cytotoxic T
cells, dendritic cells and NK cells, where
TGF  acts as negative regulator of IFNc
production via its mediators SMAD2,
SMAD3 and SMAD4. TGF  act as a
prometastatic and proangiogenic factor
in late stage cancer by constitutively
inducing epithelial to mesenchymal
transition (EMT) and tumor associated
angiogenesis.
1 The strategy of blocking
tumor-derived active TGF for therapeutic
proposes has been extensively explored.
Several therapeutic approaches target
TGF  pathway for the treatment of a
number of invasive cancer such as breast
cancer and melanoma. Intracellular inhibi-
tion of TGF  receptor I (T RI) kinase
with a small-molecule inhibitors, effec-
tively reduce the number and size of lung
metastasis in both orthotropic xenografts
and experimental metastasis model of
breast carcinoma.
3 In addition, antagonists
of TGF  binding to heteromeric receptor,
such as a soluble Fc:TGF  type II receptor
fusion protein (Fc:T RII) used decoy
receptor has shown significant reduction
of tumor cell motility, intravasation, and
metastases in three experimental models
of breast cancer. However, these treat-
ment strategies in general do not affect
cellular proliferation,
4 which indicate
that the TGF  blocking agents in vivo
does not target tumor cell proliferation.
Therefore, a pro-inflammatory stimulus
is required to alarm the immune system
against proliferating tumor cells.
The question then arises: among the
myriad pro-inflammatory cytokines known
to date, which would be best combined
to a TGF  decoy to achieve enhanced
anti-cancer immunity?
IL-2 as Partner Cytokine for sTbRII
Proinflammatory cytokines such as IL-2
constitute useful adjuvants for which
extensive clinical experience exists for the
treatment of cancer. IL-2 is well-known
factor for lymphocyte activation and clonal
expansion. IL-2 acts as autocrine factor
for T cells, supports the development of
cytotoxic T cells and stimulates NK cell
proliferation and cytotoxicity. However,
IL-2 also acts to constrain lymphoid
growth and maintain peripheral tolerance.
The development of lymphoproliferative
disorders in IL-2 knockout mice are
tangible evidence that IL-2 can operate
as both immunostimulatory and immuno-
suppressive. As immunosuppressor, IL-2
maintains peripheral tolerance by inducing
the generation of regulatory cells.
5 For
these reasons, IL-2 is considered a double-
edge sword. The versatility of its functions
is influenced by the cytokine environment
and the interaction with other cytokines.
Among them, TGF  play an essential role
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in sculpting IL-2 dependent signaling
pathway.
IL-2 and TGFb1, Dangerous
Liaisons Against Cancer Therapy
As suppressor of IL-2 signaling, TGF 1
inhibits anti-CD3 and anti-CD28 induced
IL-2 mRNA and IL-2 protein in a Smad3-
dependent manner in T cells. TGF 1 also
inhibits IL-2-induced lymphocyte prolif-
eration through a SMAD3 independent
mechanism, which may involve inactiva-
tion of phosphatase 2A (PP2A).
6
Previous analysis of IL-2R  associated
kinase activation (JAK1 and JAK3), as well
as STAT5 activation by IL-2 in the
presence or absence of TGF  show no
evidence of inhibition of Jak/Stat pathway,
but instead TGF -dependent inhibition
occurs at the nuclear level on a subset of
IL-2 target genes related to cell prolifera-
tion, including c-myc, cyclin D2 and cyclin
E. By contrast, the IL-2 mediated induc-
tion of genes involved in cell viability such
as bcl-xL and bcl-2 was not inhibited by
TGF . Thus, the combination of TGF 
and IL-2 would predictably generate a
unique pattern of gene expression that
neither IL-2 nor TGF  can generate
independently.
7
This dangerous liaison may lead to
dramatic effects in the development of an
effective anti-tumor response, which can
be severely compromised by regulatory
CD4CD25 cells that requires the presence
of both cytokines for the induction of
Foxp3.
5 With this hypothesis in mind, we
sought to block the suppressive effects of
tumor-derived TGF  in tandem with a
robust immune activation, and therefore
engineered a novel recombinant fusion
protein comprised of IL-2 fused to the
extracellular domain of TGF  receptor II,
sT RII (FIST). The coupling of these
two molecules not only recapitulates each
moiety’s function but also gives rise to a
new cytokine-like molecule with unher-
alded cell biological properties.
8
FIST, a New Strategy to
Overcome Tolerance
and Immunosuppression
We have previously demonstrated that
the fusion two cytokines with different
bioactivities not only recapitulate syn-
ergistic effects but also possess unheralded
biopharmaceutical properties not seen
by the simple combined use of each
moiety.
9 Similarly, the fusion of IL-2 and
sT RII not only promote activation of
IL-2 receptor expressing cells but also
blocks tumor derived TGF -mediated
suppression in these cell compartments
(Fig.1).
Specifically, the hyperactivation of
STAT1 is the landmark of the mechan-
ism underpinning FIST effects. STAT1
is key transcription factor implicated in
the development of TH1 cell-mediated
immunity against tumor cells. STAT1 is
a positive regulator of T-bet, the well-
known master regulator of TH1 lineage
commitment and IFNc production. In
addition, STAT1 is also considered as
the master transcriptional regulator of
antigen-specific TH1 cell trafficking in
vivo through the induction of IFNc-
inducible chemokines (CXCL9, CXCL10
and CXCL11).
10 To complete the array
of transcription factors required for an
effective anti-tumor response, Smad7 is
also overexpressed due to STAT1 hyper-
activation. Smad7 operates along with
sT RII moiety to block TGF  signaling.
8
The level of FIST-mediated hyperacti-
vation of STAT proteins is far more
potent than the resultant combination
of IL-2 receptor engagement and extra-
cellular depletion of active TGF  suggest-
ing intrinsic gain-of-function properties.
Consequently, FIST-stimulated lympho-
cytes reach a spectacular level of activa-
tion and production of pro-inflammatory
cytokine and chemokines. In summary,
FIST acts as an IFNc-like cytokine with
specificity for IL-2 receptor expressing
cells. Through STAT1 activation, FIST
involves important transcription factors for
TH1 cell-mediated immunity.
FIST, a Novel Angiostatic Factor
The formation of new blood vessels is
essential for tumors to growth more
2m m
2 in volume and progress to
metastasis. We have found that FIST
disrupts the harmonic regulation of angio-
genesis by two mechanisms: first, by
sequestering active TGF  through T RII
moiety, FIST may reduce the availability
of active TGF  for its receptors on
endothelial cells. Second, by inducing the
production of the angiostatic chemokine
CXCL10 by NK cells via STAT1 hyper-
activation, FIST alters the formation
and/or stability of blood vessels.
8 Thus
FIST targets tumor derived angiogenesis
at different checkpoints, which make
this molecule an effective angiostatic
compound for cancer therapy.
Conclusions
FIST is characterized by inhibiting TGF 
canonical pathway simultaneously with a
distinctive STAT1 hyperactivation via
IL-2 receptor on immune cells. Thus
FIST conveys a robust upregulation
of STAT1 target genes including key
factors essential for an effective TH1
cell-mediated immunity. This is the
first biological agent with the ability to
Figure 1. Schematic representation of FIST mechanism of action. Through IL-2 moiety, FIST induces
the activation of IL-2 receptor expressing immune cells, whereas the sTbRII moiety functions as
decoy receptor blocking tumor-derived TGFb-mediated suppression on immune cells.
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effectively couple anti-angiogenesis to
an immune antitumor response, result-
ing in potent anticancer properties. We
propose that the strategy of coupling
functionally distinct cytokine/receptor
pathways into a single novel fusion
cytokine-like molecule may provide a
rich and fertile source of novel biological
compounds for cancer immunotherapy.
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